Focal Segmental Glomerulosclerosis is presently considered as a set of clinical syndromes sharing a very similar common histopathologic lesion namely, focal scarring in the glomerulus followed by fibrosis, fibrous nodules, and fibric infiltrate. Although various causes may be involved in the pathogenesis of this condition, the most common mechanoreceptor sites of action are the interneurons in the optic nerve and the choroid. The choroid can be damaged due to injuries or diseases like leukemia, lymphoma, myelodysplasia, and so on. Since these choroid sites contain many cell types, a wide variety of cell-damage mechanisms have been proposed to underlie Focal Segmental Glomerulosclerosis. Focal Segmental Glomerulosclerosis is also known as nephrotic syndrome and can be effectively addressed through surgical and non-surgical treatment options.

Increasing prevalence of focal segmental glomerulosclerosis is expected to drive growth of the global focal segmental glomerulosclerosis market during the forecast period. According to the National Organization for Rare Disorders (NORD), in the U.S., focal segmental glomerulosclerosis is expected to affect around 7 people per million people in the general population.

Read more @